Journal of Clinical Oncology, Vol 6, 51-55, Copyright © 1988 by American Society of Clinical Oncology
Chemotherapy-related toxicity in infants treated according to the Second National Wilms' Tumor Study
E Morgan, E Baum, N Breslow, J Takashima and G D'Angio
Children's Memorial Hospital, Chicago, IL 60614.
Babies under 12 months of age have been included in the National Wilms'
Tumor Study (NWTS) series of clinical trials. Undue chemotherapy- related
toxicity was encountered early during the course of the second NWTS. The
prescribed doses of actinomycin D (AMD), vincristine (VCR), and Adriamycin
([ADR] doxorubicin; Adria Laboratories, Columbus, OH) were therefore
halved. The frequency of severe hematologic toxic episodes was reduced (30
of 64 or 47% for babies receiving full doses [FD], and six of 48 or 13% for
those given reduced doses [RD]). Similar reductions in pulmonary and
hepatic effects were noted, and treatment- related deaths were reduced from
6% to 0 for the FD and RD samples, respectively. These frequencies among RD
babies were similar to those encountered in 530 older children administered
FD. Reduction of dose did not compromise therapeutic effectiveness.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
